Dennis J Metzger

US Patent:

20020015693, Feb 7, 2002

Filed:

Aug 8, 2001

Appl. No.:

09/924896

Inventors:

Dennis Metzger - Sylvania OH, US
Renee Buchanan - Toledo OH, US

Assignee:

The Medical College of Ohio - Toledo OH

International Classification:

A61K039/09
A61K048/00
A61K031/715

US Classification:

424/085200, 514/044000, 424/093600, 514/054000, 424/244100

Abstract:

The present invention relates to a method of modulating an immune response to a T-cell or thymus independent antigen in a host (e.g., mammalian, including human), comprising administering to the host an effective amount of interleukin-12 (IL-12) and the T-cell independent antigen. In one embodiment, the present invention relates to a method of inducing an immune response to a TI antigen in a host (e.g., mammalian, including human), which comprises administering to the host an effective amount of interleukin-12 (IL-12) and the TI antigen. In another embodiment, the present invention relates to a method of enhancing an immune response against a TI antigen in a host, which comprises administering to the host an effective amount of IL-12 and the TI antigen. The methods of the present invention can be used, for example, to induce and or enhance a humoral immune response (IgG2a and/or IgG3 humoral immune response).

US Patent:

56653476, Sep 9, 1997

Filed:

Feb 2, 1995

Appl. No.:

8/382658

Inventors:

Dennis W. Metzger - Sylvania OH
Victor H. Van Cleave - Londonderry NH

Assignee:

Genetics Institute - Cambridge MA
Medical College of Ohio - Toledo OH

International Classification:

A61K 3820
A61K 4505

US Classification:

424 852

Abstract:

The invention relates to a method of suppressing B1 cell activity in a host (e. g. , mammalian, including human) comprising administering to the host an effective amount of IL-12 that significantly suppresses or inhibits B1 cell activity. In addition, the invention relates to a method of treating a B1 cell disorder in a host, comprising administering to the host an effective therapeutic amount of IL-12. The invention further encompasses a method of screening for substances (e. g. , proteins, peptides, small molecules) which enhance or suppress the inhibition of B1 cell activity by IL-12. The invention also relates to a substance identified by the methods of screening for a substance which enhances or suppresses IL-12 inhibition of B1 cell activity.

US Patent:

63031140, Oct 16, 2001

Filed:

Mar 5, 1998

Appl. No.:

9/035594

Inventors:

Dennis W. Metzger - Sylvania OH
Renee M. Buchanan - Toledo OH

Assignee:

The Medical College of Ohio - Toledo OH

International Classification:

A61K 3820

US Classification:

424 852

Abstract:

The present invention relates to a method of modulating an immune response to a T-cell or thymus independent antigen in a host (e. g. , mammalian, including human), comprising administering to the host an effective amount of interleukin-12 (IL-12) and the T-cell independent antigen. In one embodiment, the present invention relates to a method of inducing an immune response to a TI antigen in a host (e. g. , mammalian, including human), which comprises administering to the host an effective amount of interleukin-12 (IL-12) and the TI antigen. In another embodiment, the present invention relates to a method of enhancing an immune response against a TI antigen in a host, which comprises administering to the host an effective amount of IL-12 and the TI antigen. The methods of the present invention can be used, for example, to induce and or enhance a humoral immune response (IgG2a and/or IgG3 humoral immune response).

US Patent:

59852640, Nov 16, 1999

Filed:

Mar 5, 1998

Appl. No.:

9/035593

Inventors:

Dennis W. Metzger - Sylvania OH
Bernard P. Arulanandam - Toledo OH

Assignee:

The Medical College of Ohio - Toledo OH

International Classification:

A61K 4505
A61K 3900

US Classification:

424 852

Abstract:

The present invention relates to a method of inducing a Th1-like response against a pathogen in a neonatal host, which comprises administering to the neonatal host an effective amount of IL-12 and an antigen of the pathogen. Also encompassed by the present invention is a method of overcoming suppression of interferon-. gamma. (IFN-. gamma. ) expression in a neonatal host due to exposure of the neonatal host to a pathogen or an antigen, which comprises administering to the neonatal host an effective amount of IL-12 and the antigen. The present invention also relates to a method of enhancing the cytokine expression against or in response to a pathogen in a neonatal host, which comprises administering to the neonatal host an effective amount of IL-12 and an antigen of the pathogen.